Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Check out some of our latest original content that was created and distributed as part of our ongoing collaborations with IR firms and other companies.

Clene Inc. (NASDAQ: CLNN) Closes $7.3 Million Registered Direct Offering and Concurrent Private Placements

  • Proceeds from the offerings will support the company’s operations into the first quarter of 2025.
  • Clene also amended its existing debt facility with Avenue Venture Opportunities Fund, L.P. to reduce or defer future monthly principal payments and to extend principal amortization period and the final maturity date into the first half of 2025.
  • The company’s lead drug candidate, CNM-Au8® has been shown to restore and protect neurological function, offering new hope for patients with ALS and other neurodegenerative conditions.
  • Clene is seeking an accelerated approval pathway for CNM-Au8 for ALS, with a meeting scheduled with the FDA before the end of November.

Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) multiple sclerosis (“MS”) and Parkinson’s Disease (“PD”), announced the successful closing of a $7.3 million registered direct offering and concurrent private placements, designed to boost its capital position during a crucial phase in its on-going operations.

The registered direct offering and concurrent private placements of common stock and warrants with a healthcare-focused institutional investor and existing shareholders, including insiders, brought total gross proceeds of $7.3 million, with the potential for additional capital in the future through the exercise of warrants (https://ibn.fm/m8dCM).

The offering was led by a healthcare-focused institutional investor with participation from SymBiosis; founding investor Kensington Capital Holdings; Clene’s Chairman of the Board of Directors, Chief Executive Officer and Chief Scientific Officer and Founder; along with support from several other previously existing shareholders.

Clene also announced an amendment of its existing debt facility with Avenue Venture Opportunities Fund, L.P. such that future monthly principal payments are reduced or deferred, and the principal amortization period and maturity date of the loan will be extended into the first half of 2025.

This financing and debt restructuring is expected to provide Clene with essential funding for its operations into the first quarter of 2025 which will support upcoming regulatory milestones, including the upcoming meeting with the U.S. Food and Drug Administration (“FDA”) to discuss the potential to file a new drug application for lead candidate CNM-Au8 for ALS under an accelerated approval pathway.

This financing follows two encouraging Phase 2 clinical trials, RESCUE-ALS and HEALEY ALS Platform Trials, where participants who were administered CNM-Au8, saw significant improvement in survival rates, functional status and combined assessment of function and survival.

Developed as an oral suspension of gold nanocrystals, CNM-Au8 works by improving cellular energy production and utilization, which is critical for maintaining neuronal health. In both clinical trials and compassionate use programs, CNM-Au8 has already been shown to improve central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the nicotinamide adenine dinucleotide (“NAD”) pathway while reducing oxidative stress. By targeting mitochondrial dysfunction, CNM-Au8 aims to provide neuroprotection and promote remyelination, potentially altering the course of neurodegenerative conditions.

Commenting on the closing of the financing and upcoming plans, Chairman of the Board David Matlin said the company appreciated the support it obtained from its new healthcare-focused institutional investor as well as existing shareholders. “The capital raised in this offering along with the debt principal deferral from Avenue will allow the company to fund itself while in discussions with the FDA to potentially file an NDA under the accelerated approval pathway by year end,” Matlin added. “Most importantly, this financing also enables people with ALS who currently take CMN-Au8 under our compassionate use programs to continue receiving drug while Clene discusses its data with the FDA.”

For more information, visit the company’s website at www.Clene.com.

NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
[email protected]

MissionIR is powered by IBN

Posted in Clene Inc. CLNN | Leave a comment

SOBRsafe Inc.’s (NASDAQ: SOBR) Disruptive Technology Poised to Become the Global Standard for Alcohol Monitoring and Detection

  • Alcohol detection and monitoring devices have been in use for years, but the need for faster, discreet technology capable of delivering real-time results became more apparent in the mid-2010s
  • In 2015 and 2016, the NIAAA announced challenges seeking alcohol monitoring solutions that provide real-time results; the winning entries were wearable wristbands still at the prototype stage
  • Fast-forward to today, and SOBRsafe, a company providing next-generation alcohol detection technology, commercializes its market-validated SOBRcheck(TM) stationary alcohol screening device and the SOBRsure(TM) wearable wristband
  • SOBRsafe’s devices feature highly precise sensors that are calibrated for early, low alcohol detection, beginning at about 20 minutes, compared to 45-60 minutes for the leading mandatory ankle monitor
  • The company believes its disruptive breakthrough technology could become the global standard for alcohol monitoring and detection, replacing legacy products and testing methods

In 2015 and 2016, the National Institute on Alcohol Abuse and Alcoholism (“NIAAA”), a part of the National Institutes of Health (“NIH”), challenged innovators and entrepreneurs to create a “wearable or otherwise discreet device capable of measuring blood alcohol level in real-time.” The challenge aimed to help solve the disadvantages of the then-preferred technologies for alcohol monitoring.

“Current technology for continuous alcohol monitoring takes a reading every 30 minutes. We are seeking a solution that improves on this interval and most closely approximates real-time monitoring and data collection,” stated the circular from NIAAA explaining the rationale behind the 2015 challenge (https://ibn.fm/EhUO8).

The winners designed wearable wrist monitors that measure transdermal alcohol concentrations (“TAC”) (https://ibn.fm/fpXye). While these winning entries were prototypes, the competition perhaps inspired the modern alcohol detection and monitoring landscape. Today, there are validated, commercially available transdermal alcohol monitoring devices available on the market, some more capable than others.

One company in particular, SOBRsafe (NASDAQ: SOBR), commercializes its SOBRcheck(TM) stationary screening and SOBRsure(TM) wearable monitoring solutions, which utilize a proprietary transdermal technology that simplifies the alcohol detection process. According to the company, the SOBRsafe transdermal detection technology pairs a NIAAA-awarded transdermal gas sensor with proprietary algorithms to capture alcohol vapor excreted through skin pores alongside other contents of sweat.

The highly precise sensor is engineered and calibrated for early, low alcohol detection, beginning at about 20 minutes, compared to 45-60 minutes for the leading mandatory ankle monitor. The company’s technology, therefore, detects alcohol 2-3x faster than other transdermal alcohol detection solutions (https://ibn.fm/Vd9GI).

The SOBRcheck(TM) stationary screening device is designed for facility access control, centralized fleets, and monitoring patients in point-of-care behavioral health facilities. It features the aforementioned gas sensor, which determines the presence or absence of alcohol, and a biometric sensor that scans a fingerprint to authenticate a user’s identity. The device provides administrators with real-time, time-stamped results, delivered via the company’s SOBRsafe software. One adopter of the SOBRcheck(TM) solution, Alternatives Inc., in fact, noted that SOBRcheck(TM) is faster and more sanitary than breathalyzers (https://ibn.fm/tM191).

The SOBRsure(TM) remote monitoring device, on the other hand, has the same footprint as a wearable wristband. It is designed to discreetly and continuously monitor the presence of alcohol in the system, freeing users from scheduled testing and building trust faster thanks to its continuous monitoring attribute. It also eliminates the embarrassment that accompanies using blow devices or providing urine samples.

Like the SOBRcheck(TM) device, the SOBRsure(TM) features the award-winning gas sensor, as well as GPS tracking capabilities. It relays the results continuously to an app-based reporting interface and sends notifications to parents or administrators whenever it detects alcohol. It also sends alerts containing location data whenever it is removed.

Since the fourth quarter of 2023, SOBRsafe has been marketing its alcohol detection and monitoring solutions to the behavioral health market. “In 2024, and consistent with our strategy, we have now established our technology, with our first revenue-generating customers in behavioral health growing to 35 accounts in the first and second quarters of this year. In addition, we entered the equivalent verticals in Australia and New Zealand and are gaining traction through a channel partner that we’re very, very excited about,” said SOBRsafe CEO Dave Gandini in a recent video update (https://ibn.fm/My3XB).

The company is also targeting further international expansion and has invested in a marketing campaign that aims to present its solutions to more than 45,000 behavioral health decision-makers in the U.S. “We believe that our approach will increase demand, drive sales and gain market share for us in the fourth quarter and on into 2025,” Gandini continued.

The company believes its disruptive breakthrough technology could become the global standard for alcohol monitoring and detection, replacing legacy products and testing methods. And with its international expansion and robust marketing campaign underway, coupled with the strong adoption in the core behavioral health vertical since late 2023, the company is a worthy consideration for investors.

For more information, visit the company’s website at www.SOBRsafe.com.

NOTE TO INVESTORS: The latest news and updates relating to SOBR are available in the company’s newsroom at https://ibn.fm/SOBR

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
[email protected]

MissionIR is powered by IBN

Posted in SOBRsafe Inc. SOBR | Leave a comment

MissionIRNewsBreaks – SuperCom Ltd. (NASDAQ: SPCB) Announces 5-Year Contract to Provide Advanced Electronic Monitoring Solutions to the Israel Prison Service State Agency

SuperCom Ltd. (NASDAQ: SPCB), a global provider of secure solutions for the e-Government, IoT, and cybersecurity sectors, and its prime partner Electra, a security services provider in Israel, have been awarded a 5-year contract by the Israel Prison Service state agency (“IPS”). The full-service contract, which is already in effect and includes an optional extension of up to four more years, mandates SuperCom to deploy its PureSecurity Electronic Monitoring (“EM”) Suite, namely PureCom, PureTrack, PureTag, and PureBeacon. The contract encompasses all EM offender programs within Israel, including the existing Home Detention Monitoring program and additional GPS Tracking programs, and is expected to have about 1,500 enrollees, with the potential for future expansion.

“We are deeply honored to support Israel’s public safety infrastructure during these challenging times,” stated Ordan Trabelsi, President and CEO of SuperCom. “Our mission goes beyond business; it is about contributing to the safety and resilience of Israel. By providing the Israel Prison Service state agency with our advanced electronic monitoring solutions, we reaffirm our unwavering commitment to making Israel safer for all its citizens.”

To view the full press release, visit https://ibn.fm/KvPns

About SuperCom

Since 1988, SuperCom has been a global provider of traditional and digital identity solutions, providing advanced safety, identification, and security solutions to governments and organizations, both private and public, worldwide. Through its proprietary e-Government platforms and innovative solutions for traditional and biometrics enrollment, personalization, issuance, and border control services, SuperCom has inspired governments and national agencies to design and issue secure Multi-ID documents and robust digital identity solutions to its citizens and visitors. SuperCom offers a unique all-in-one field-proven RFID & mobile technology and product suite, accompanied by advanced complementary services for various industries, including healthcare and homecare, security and safety, community public safety, law enforcement, electronic monitoring, and domestic violence prevention. For more information, visit the company’s website at www.SuperCom.com.

NOTE TO INVESTORS: The latest news and updates relating to SPCB are available in the company’s newsroom at http://ibn.fm/SPCB

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
[email protected]

MissionIR is powered by IBN

Posted in SuperCom Ltd. SPCB | Leave a comment

Foremost Clean Energy Ltd. (NASDAQ: FMST) (CSE: FAT) Is ‘One to Watch’

  • In September 2024, Foremost announced an option agreement with Denison Mines for 10 uranium projects in Saskatchewan’s Athabasca Basin.
  • The company has aggressive exploration plans across its 330,000-acre uranium portfolio, with both shallow and deep targets.
  • The Athabasca Basin is known for hosting some of the richest uranium deposits in the world, with strong infrastructure supporting exploration.
  • Foremost’s partnerships with Denison Mines and local geological firms, along with its strong management team, position it well for future success.
  • The company also holds a secondary portfolio of lithium projects, covering over 50,000 acres, providing additional long-term growth potential.

Foremost Clean Energy (NASDAQ: FMST) (CSE: FAT), formerly Foremost Lithium Resource & Technology Ltd., is an emerging North American energy exploration company focused on supporting the clean energy transition. Foremost holds an option to acquire an interest in 10 prospective uranium properties, covering over 330,000 acres in the uranium-rich Athabasca Basin of Saskatchewan.

The company aims to address the growing demand for uranium, a critical element in global energy transition efforts. In partnership with Denison Mines (NYSE American: DNN), Foremost is pursuing a disciplined and dynamic exploration strategy. Foremost’s mission is to make significant discoveries through active exploration of its promising, underdeveloped land holdings in the Athabasca Basin. Its uranium portfolio includes projects at various stages of exploration, from grassroots initiatives to advanced, drill-ready targets.

As the world shifts toward a clean energy future, uranium will play a key role as a low-cost, emission-free fuel for electricity generation. Foremost’s development plans aim to provide low-cost uranium solutions, capitalizing on the global movement to decarbonize power grids.

In addition to its uranium assets, Foremost holds a secondary portfolio of lithium projects, spanning more than 50,000 acres across Manitoba and Quebec.

Foremost is headquartered in Vancouver, British Columbia.

Projects

Foremost’s portfolio, under its option agreement with Denison Mines, includes 10 properties, many located near high-profile uranium operations like the McClean Lake mill and Cigar Lake mine. Seven of these properties are situated in the eastern portion of the Athabasca Basin, close to well-established infrastructure, while three lie in the northwestern portion of the basin – an area with high potential for new discoveries but little previous exploration.

Through the option agreement, Foremost may earn up to 70% of Denison’s interest in the properties. Denison currently owns 100% of nine properties. The agreement includes three phases during which Foremost must issue shares to Denison, appoint Denison representatives to its board, provide cash or share payments, and incur specific exploration expenditures to increase its ownership stake.

Market Opportunity

According to RationalStat, the global uranium mining market was valued at $8.09 billion in 2023 and is projected to grow to $11.38 billion by 2030, with a CAGR of over 5%.

Uranium, used in nuclear reactors, produces energy through nuclear fission and is considered a clean energy source as it emits no greenhouse gases during operation. The push to reduce carbon emissions and combat climate change is driving the demand for nuclear energy, and thus, uranium.

The uranium market is also poised for growth due to the phasing out of fossil fuels, mine closures, production disruptions, and geopolitical factors such as trade sanctions on Russia and civil unrest in Niger, which have highlighted the urgency for reliable uranium supplies.

Canada, producing about 15% of the world’s uranium annually, is the second-largest global uranium producer, after Kazakhstan.

Management Team

Jason Barnard, CEO, President, and Executive Board Member of Foremost, has over 31 years of capital markets experience. He has been directly involved in raising over $500 million for mining and exploration companies. Mr. Bernard began his career with McDermid St. Laurence Securities and later worked at Canaccord Genuity. He has been with Foremost since 2016 and is its largest shareholder. He holds a bachelor’s degree in economics from Carleton University.

Dong Shim, CPA, CA, serves as CFO. He is a partner at Shim & Associates LLP and is registered as a CPA in British Columbia and Illinois. Mr. Shim brings extensive accounting and auditing expertise, having worked with both U.S. and Canadian junior mining and tech companies.

Christina Barnard, COO, has over 20 years of experience in business management, media and marketing. Her career includes a decade as a senior marketing and media advisor for a national public company and roles in corporate communications and strategy for several public companies.

For more information, visit the company’s website at https://foremostcleanenergy.com.

NOTE TO INVESTORS: The latest news and updates relating to FMST are available in the company’s newsroom at https://ibn.fm/FMST

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
[email protected]

MissionIR is powered by IBN

Posted in Foremost Clean Energy Ltd. FMST | Leave a comment

MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Featured in Fireside Chat at 2024 Healthcare Virtual Summit

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be participating in the upcoming 2024 Healthcare Virtual Summit. The summit, which is presented by Maxim Group LLC, is scheduled for Oct. 16, 2024. According to the announcement, CNS Pharmaceuticals CEO John Climaco will be part of a fireside chat, slated to begin at 4 p.m. ET during the one-day event. In addition to the fireside chat, the summit will include presentations, interactive discussions and topical industry panels with an array of biotechnology, diagnostic, medical device, and healthcare information technology companies and experts.

To view the presentation or find out more about the event, visit https://ibn.fm/ZxoI7

To view the full press release, visit https://ibn.fm/RlfLS

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anticancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. For more information about the company, please visit www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
[email protected]

MissionIR is powered by IBN

Posted in CNS Pharmaceuticals Inc. CNSP | Leave a comment

MissionIRNewsBreaks – SOBR Safe Inc. (NASDAQ: SOBR) Reports on Private Placement Valued at Estimated $8.2M

SOBRsafe (NASDAQ: SOBR), a provider of next-generation, transdermal alcohol-detection solutions, has released certain information regarding a private placement. The placement, which is with certain institutional investors, is projected to result in an estimated $8.2 million for the company, before the deduction of standard fees and costs. SOBRsafe anticipates using the funds for working capital and general corporate purposes. The company plans on issuing 2,024,691 units in connection with the placement, with each unit sold at $4.05. The announcement noted that each unit will comprise one share of common stock (or one prefunded warrant in lieu thereof), two Series A warrants and one Series B warrant. The placement is expected to close today and is subject to customary closing conditions. Aegis Capital Corp. is acting as placement agent for the private placement.

To view the full press release, visit https://ibn.fm/1geWC

About SOBR Safe Inc. 

SOBRsafe offers an advanced transdermal (touch-based) technology that detects and instantaneously reports in real time the presence of alcohol as emitted through a user’s skin — no breath, blood or urine sample is required. Alcohol misuse is the fourth-leading cause of preventable death in America and the seventh worldwide. Yet prevention and monitoring solutions have not kept pace with this epidemic. Legacy technologies are invasive, inefficient, unhygienic and unconnected. There has to be a better way. Enter SOBRsafe. With a powerful backend data platform, SOBRsafe provides next-generation, passive-detection technology for the behavioral health, judicial and consumer markets, as well as for licensing and integration. The SOBRsafe technology is commercially available for point-of-care screening (SOBRcheck) and continuous monitoring (SOBRsure). SOBRsafe is on a mission to create better outcomes and save lives. For more information about the company, visit www.SOBRsafe.com.

NOTE TO INVESTORS: The latest news and updates relating to SOBR are available in the company’s newsroom at http://ibn.fm/SOBR

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
[email protected]

MissionIR is powered by IBN

Posted in SOBRsafe Inc. SOBR | Leave a comment

MissionIRNewsBreaks – NextPlat Corp (NASDAQ: NXPL) Announces ‘Significant’ Extension and Expansion of Exclusive Distribution Agreement with OPKO Health

NextPlat (NASDAQ: NXPL, NXPLW), a global e-commerce provider, today announced that its original exclusive e-commerce distribution contract with OPKO Health Inc. (NASDAQ: OPK) has been extended for four years and expanded to include additional e-commerce platforms and digital and social media marketing across China. The original agreement allowed NextPlat to sell OPKO Health Europe’s nutraceutical and veterinary products on the Tmall Global e-commerce platform only. According to the announcement, the expanded contract also grants NextPlat the exclusive rights to sell and market OPKO products in Japan.

“The significant extension and expansion of our agreement with OPKO is evidence of the trust and confidence they have in our ability to penetrate the Chinese market, creating valuable new revenue streams for their business,” stated Charles M. Fernandez, Executive Chairman and CEO of NextPlat. “We believe our ability to tap into the broad reach of the most popular online and digital channels in China combined with highly targeted, on the ground experiential marketing capabilities, makes our e-commerce development program a compelling solution for any brand that wishes to reach the Chinese consumer and well enter other large regional markets such as Japan.”

To view the full press release, visit https://ibn.fm/XY39U

About NextPlat Corp

NextPlat is a global e-commerce platform company created to capitalize on multiple high-growth sectors and markets including technology and healthcare. Through acquisitions, joint ventures and collaborations, the company intends to assist businesses in selling their goods online, domestically, and internationally, allowing customers and partners to optimize their e-commerce presence and revenue. NextPlat currently operates an e-commerce communications division offering voice, data, tracking, and IoT products and services worldwide as well as pharmacy and healthcare data management services in the United States through its subsidiary, Progressive Care Inc.

NOTE TO INVESTORS: The latest news and updates relating to NXPL are available in the company’s newsroom at https://ibn.fm/NXPL

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
[email protected]

MissionIR is powered by IBN

Posted in NextPlat Corp. NXPL | Leave a comment

D-Wave Quantum Inc. (NYSE: QBTS) Adds New Chief Human Resources Officer to Executive Management Team

  • Sophie Ames will lead the company’s human capital innovation strategy to support its next stage of growth.
  • Her prior experience includes leadership roles at top public and private technology and services companies, including Mitel, ServiceMax, Avaya and more.
  • D-Wave CEO Dr. Alan Baratz said Ames’ proven 25-year track record will help D-Wave’s employee value proposition stand out in a highly competitive labor marketplace.

D-Wave Quantum (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software and services, and the first commercial provider of quantum computers, recently announced the appointment of a new chief human resources officer to its executive team (https://ibn.fm/elbbu).

The new chief human resources officer, Sophie Ames, brings more than 25 years of broad international experience in the human resources field. Ames has held leadership roles with various top public and private international technology and services companies, such as Mitel, ServiceMax, Veritas Technologies LLC, Avaya, Amdocs, and Thomson Legal & Regulatory, establishing a strong track record for building agile, high performance HR teams and scaling organizations for growth.

In her new role at D-Wave, Ames will spearhead the company’s global human capital innovation strategy designed to help support the company’s next stage of growth. This includes talent acquisition, learning and development, organizational effectiveness, compensation and benefits, and HR operations. She will focus on building the connection between the company’s performance, people and processes across the entire employee lifecycle engagement.

“I couldn’t be more excited to join D-Wave and be part of a company leading the next technology innovation revolution. It is an incredible opportunity to help shape the future of an industry and to bring the human capital function to the forefront of growth,” said Ames.

D-Wave CEO Dr. Alan Baratz echoed this excitement in welcoming Ames to D-Wave, noting, “Sophie’s proven track record and experience will add strategic value to the human resources function as we continue to build and differentiate D-Wave’s employee value proposition in a distinctive labor marketplace.”

For more information, visit the company’s website at www.dwavequantum.com.

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

Forward Looking Statements

Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including the risks set forth under the heading “Risk Factors” discussed under the caption “Item 1A. Risk Factors” in Part I of our most recent Annual Report on Form 10-K or any updates discussed under the caption “Item 1A. Risk Factors” in Part II of our Quarterly Reports on Form 10-Q and in our other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to us on the date hereof. We undertake no duty to update this information unless required by law.

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
[email protected]

MissionIR is powered by IBN

Posted in D-Wave Quantum Inc. QBTS | Leave a comment

MissionIRNewsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Forecasts $75M in GAAP Revenue Over Next 6 Months, Implements Immediate Measures to Cut Overall Expenses

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, today announced that it expects to ramp up its commercial sales to a monthly average of $12.5 million. As a result, the company forecasts $75 million in estimated GAAP revenue over the next six months from both Mullen Commercial’s and its subsidiary Bollinger Motors’ sales opportunities and pilot programs. The announcement also noted that the company is taking immediate steps to reduce its overall spend (operating and investing cash flows) from $12.8 million to $7.3 million. The $5.5 million cut is driven by a 20% reduction in headcount, elimination of passenger vehicle programs, and facility consolidations.

“As Bollinger focuses on B4 ramp up production volume and Mullen’s commercial vehicle sales momentum continues, I remain confident that through continued focus on revenue growth and expense reduction our near term cash flow will continue to improve,” stated David Michery, CEO and Chairman of Mullen.

To view the full press release, visit https://ibn.fm/buHXd

About Mullen Automotive Inc.

Mullen Automotive is a Southern California-based automotive company building the next generation of commercial electric vehicles (“EVs”) with two United States-based vehicle plants located in Tunica, Mississippi, (120,000 square feet) and Mishawaka, Indiana (650,000 square feet). In August 2023, Mullen began commercial vehicle production in Tunica. In September 2023, Mullen received IRS approval for federal EV tax credits on its commercial vehicles with a Qualified Manufacturer designation that offers eligible customers up to $7,500 per vehicle. As of January 2024, both the Mullen ONE, a Class 1 EV cargo van, and Mullen THREE, a Class 3 EV cab chassis truck, are California Air Resource Board (“CARB”) and EPA certified and available for sale in the U.S. The CARB-issued HVIP approval on the Mullen THREE, Class 3 EV truck, provides up to a $45,000 cash voucher at time of vehicle purchase. The company has also recently expanded its commercial dealer network to seven dealers with the addition of Papé Kenworth. Other previously announced dealers include Pritchard EV, National Auto Fleet Group, Ziegler Truck Group, Range Truck Group, Eco Auto, and Randy Marion Auto Group, providing sales and service coverage in key Midwest, West Coast, Pacific Northwest, New England and Mid-Atlantic markets. The company has also announced Foreign Trade Zone (“FTZ”) status approval for its Tunica, Mississippi, commercial vehicle manufacturing center. FTZ approval provides a number of benefits, including deferment of duties owed and elimination of duties on exported vehicles. For more information about the company, visit www.MullenUSA.com.

NOTE TO INVESTORS: The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
[email protected]

MissionIR is powered by IBN

Posted in Mullen Automotive Inc. MULN | Leave a comment

Annovis Bio Inc. (NYSE: ANVS) Seeking to Strengthen Intellectual Property Portfolio, Protecting Multifaceted Approach for Treatment of Neurodegenerative Diseases

  • Annovis Bio recently filed three new patents covering combinations of buntanetap, its lead compound, with a GLP-1 agonist (such as dulaglutide/Trulicity) and with PDE5 inhibitors (such as sildenafil/Viagra), as well as a combination of all three
  • The company believes these combinations create a broader approach to treating neurodegenerative diseases
  • Preclinical studies have demonstrated these combinations significantly improve cognition in Alzheimer’s mouse models
  • Combinations of buntanetap with PDE5 inhibitors and GLP-1 agonists are now ready to enter phase 3 clinical studies (buntanetap is in phase 3, and a number of PDE5 inhibitors and GLP-1 agonists are already on the market)

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company developing transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), recently filed three new patents (https://ibn.fm/wWksA). The patent applications seek protection for innovative combination therapies involving buntanetap that improve cognition beyond normal levels.

Specifically, the patent filings cover buntanetap combined with a glucagon-like peptide-1 (“GLP-1”) agonist, buntanetap combined with a phosphodiesterase 5 (“PDE5”) inhibitor, and a combination of all three. According to the company, these combinations create a multi-sided approach to treating neurodegenerative diseases.

The motivation to seek patent protection stems from the successes of recent preclinical studies, which have provided compelling results that demonstrate the strong potential for the combinations to enhance cognition. Data from these studies have shown that buntanetap combined with PDE5 inhibitors or GLP-1 agonists improves cognitive function in Alzheimer’s mouse models beyond levels observed in healthy controls.

Maria Maccecchini, Ph.D., Founder, President and CEO of Annovis, noted, “Our early data suggests a strong synergistic effect from combining these drugs, resulting in significant cognitive enhancement.” Maria went on to state that the combination of buntanetap with Trulicity and Viagra has the potential to “restore cognition to healthy levels” and improve it “beyond normal level, offering new hope in the fight against dementia.”

According to an August 6 news release, buntanetap significantly amplifies the effects of Trulicity on memory and learning, leading to a “6- to 10-fold increase in efficacy,” according to Maria. The company observes that this synergy helps enhance treatment outcomes while simultaneously lessening potential side effects (https://ibn.fm/0zRY1).

Buntanetap targets neurodegeneration by inhibiting the production of various neurotoxic proteins, including TDP43, alpha-synuclein, tau, and amyloid beta. It improves the affected function in neurodegenerative diseases, enhances cognition in early AD patients, improves motor function and stops cognitive decline in PD patients.

The company’s recent Phase 2/3 study of buntanetap in patients with early (mild to moderate) AD showed a statistically significant improvement in cognition. The Phase 2/3 study gave the company valuable information for a planned Phase 3 pivotal trial (https://ibn.fm/sVv02). In addition, the company has separately completed a Phase 3 study of buntanetap in patients with early PD (https://ibn.fm/FIM3D).

“Since buntanetap has completed Phase 3 studies as a standalone treatment, and a number of GLP-1 agonists and PDE5 inhibitors are FDA-approved, these combinations are well positioned for Phase 3 human trials,” expressed Maria in the Sept. 30 news release announcing the patent filings.

The new patent applications are expected to further strengthen the company’s expansive intellectual property portfolio. Annovis currently has more than 35 total issued patents, plus plenty more pending applications in various jurisdictions, according to its latest Form 10-K filing (https://ibn.fm/YzxJB).

The issued patents and pending applications speak to the company’s resolve to “protect and enhance the proprietary technologies, inventions and improvements that we believe are important to our business, including seeking, maintaining and defending patent rights, whether developed internally or licensed from third parties,” as a source of its unique value to shareholders and competitive advantage.

For more information about the company, visit www.AnnovisBio.com, and social channels LinkedInX and YouTube.

NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
[email protected]

Posted in Annovis Bio Inc. ANVS | Leave a comment